भारत सरकार | GOVERNMENT OF INDIA
inner page banner

FAQ's

1. What is meant by "biological resources"?

As per Section 2(c) of the BD Act, the biological resources include plants, animals, micro-organisms or parts of their genetic material and derivatives (excluding value added products) with actual or potential use or value for humanity, but does not include human genetic material.

2. Why was the Biological Diversity Act, 2002 enacted?

In compliance with our obligations under CBD, the Biological Diversity Act was enacted with the core objectives to conserve the biological resources, ensure sustainable use of its components, and promote the fair and equitable sharing of benefits arising from the utilisation of such biological resources and or associated knowledge

3. What is the concept and purpose of “access and benefit sharing”?

ABS mechanism has been evolved under the CBD and Nagoya Protocol to ensure that the users of biological resources share a portion of their gains/profits with the conservers of these resources which serves as an incentive for them to continue their efforts in conserving, preserving and maintaining the biological diversity and TK associated thereto. This works on the principle of equity which contributes to the conservation and sustainable use of the components of biological resources.

4. Has India’s status as a signatory to the CBD helped the tribal people and local communities safeguard their TK and derive benefits from its utilisation?

Yes. As a signatory to the CBD, India has enacted BD Act, 2002, to conserve biological resources and associated TK of the tribal people and local communities. The BD Act mandates the establishment of BMCs, at the local level, which documents biological diversity and associated TK through the preparation of People’s Biodiversity Registers (PBRs).

The Act also regulates access to biological resources and associated TK. Access for research or commercial utilisation requires prior informed consent (PIC) of the concerned communities, obtained through the relevant BMCs as provided under Section 41 of the Act. Furthermore, the Act ensures fair and equitable sharing of benefits arising out of the use of biological resources and associated TK with the concerned tribal/ local communities or the original knowledge holders. These provisions empower local communities and help safeguard their TK.

5. What is the United Nations Convention on Biological Diversity (CBD)?

The variety of life and lifeforms referred to as “biodiversity” is the source of support, sustenance and succour to all the lifeforms, including humans, on earth. Rapid loss of biological diversity and its unfair commercial application, owing to a host of reasons - unplanned development, over exploitation, unscientific use and commercial application, piracy from host nation and communities of people etc., all over the world, became a matter of grave concern of humanity. To arrest such a trend and to take measures for its conservation, its sustainable and fair use, a new international legal arrangement was crafted. CBD is the outcome of such a deliberation and the first major international legal arrangement, under the United Nations. Ratified by 196 Countries, it promotes the conservation of biological diversity, the sustainable use of its components, and the fair and equitable sharing of benefits arising from the utilisation of genetic resources. The Convention was opened for signature on 5 June 1992 at the United Nations Conference on Environment and Development (the Rio “Earth Summit”). It remained open for signature until 4 June 1993, by which time it had received 168 signatures. The Convention entered into force on 29 December 1993, which was 90 days after the 30th ratification.

6. How does CBD recognise the biological resources at the country level?

The CBD reaffirms the sovereign rights of the Parties (i.e., member countries) over their biological resources. It encourages countries to facilitate appropriate access to genetic resources by other Parties, subject to their national legislations.

While encouraging access to genetic resources by other Parties, the CBD makes it clear that such access is subject to prior informed consent (PIC) and mutually agreed terms (MAT), as determined by the provider country (country providing the genetic resource(s) and associated traditional knowledge).

Additionally, the CBD promotes the fair and equitable sharing of benefits arising from the utilization of genetic resources, including benefits derived from associated traditional knowledge (TK), innovations, and practices of indigenous and local communities. CBD provides the legal framework for the member countries to evolve their own legislations, with institutions of enforcement for achieving its goals that would include, regulation of access, determination of the terms for benefit sharing, and ensuring fairness and equity in sharing of benefits arising from the commercial application of biodiversity.

7. Who is considered as Section 3(2) person under the amended Act?

  1. a person who is not a citizen of India;
  2. a citizen of India, who is a non-resident as defined in clause (30) of Section 2 of the Income-tax Act, 1961;
  3. a body corporate, association or organization;
    1. Not incorporated or registered in India; or
    2. Incorporated or registered in India under any law for the time being in force, which is controlled by a foreigner within the meaning of clause (27) of Section 2 of the Companies Act, 2013.

8. Who determines the fair and equitable benefit-sharing component?

According to Section 2(g) of the Act, “fair and equitable benefit sharing” means sharing of benefits as determined by the NBA under Section 21.

Section 21 states that the NBA will determine the benefit sharing. The Authority in consultation with the local bodies impose terms and conditions while granting approvals, for securing equitable sharing of benefits.

9. Whether approval is necessary for publication of results of research on any biological resources occurring in India, in a research paper or for dissemination in any workshop or seminar?

No. Section 4 exempts publication of research papers on any biological resources occurring in or obtained or accessed from India or dissemination of knowledge in any seminar or workshop involving financial benefit, provided such publication or dissemination is in conformity with the guidelines issued by the Central Government.

10. Does the BD Act provide for any exemptions?

The Act provides for the following exemptions:

  1. Access by Section 7 entities for research / bio-survey / bio-utilization: Access to biological resources or knowledge associated thereto by a Section 7 entity for undertaking research or bio-survey and bio-utilisation in India is exempted from seeking approval of SBB/NBA under the Act.
  2. Value-added products: Access to value-added products, which may contain portions or extracts of plants and animals in unrecognisable and physically inseparable form {Sec. 2(p)}.
  3. Codified traditional knowledge and cultivated medicinal plants: Codified traditional knowledge, cultivated medicinal plants and their products, local people and communities of the area, including growers and cultivators of biodiversity and vaids, hakims and registered AYUSH practitioners only, who have been practising indigenous medicines, including Indian systems of medicine as profession for sustenance and livelihood are exempted under Section 7 of the Act.
  4. Conventional breeding: Accessing biological resources for conventional breeding or traditional practices in use in any agriculture, horticulture, poultry, dairy farming, animal husbandry or beekeeping, in India {Section 2(f)}.
  5. Academic dissemination: Publication of research papers or dissemination of knowledge, in any seminar or workshop involving financial benefit, if such publication is in conformity with the guidelines issued by the Central Government from time to time (first proviso clause to Section 4).
  6. Collaborative research: Transfer or exchange of biological resources or TK under collaborative research projects between Government-sponsored institutions and such institutions in other countries are exempted subject to conformity to the policy guidelines issued by the Central Government (Section 5).
  7. Normally traded as commodities: Biological resources when normally traded as commodities or to the items derived from them, including agricultural wastes, as notified and cultivated medicinal plants and their products for entities covered under Section 7, registered as per the regulations made or as may be prescribed, notified by the Central Government (Section 40).
  8. Crops under ITPGRFA: Accessing the crops from amongst the crops listed at Annex-I of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA), as notified by the Department of Agriculture and Cooperation, Ministry of Agriculture, Government of India from time to time, is exempted from the provisions of Sections 3 and 4 of the Act, for the purpose of utilization and conservation for research, breeding and training for food and agriculture.
  9. Approvals under the PPVFRA: Any person who has been given any approval or granted any right under any law relating to protection of plant varieties enacted by the Parliament to the extent that such approvals or rights given under that Act does not require similar approval under the BD Act (Section 59-A).

11. What is the benefit-sharing component payable to the NBA by the applicant for accessing the biological resources for commercial utilisation?

As per regulation 4 of the BD (ABS) Regulations, 2025, the applicant shall have to pay the benefit sharing amount to the NBA as per the slabs prescribed below:

Sl. No.Annual turnover of the entity (in Indian rupee)Amount payable on account of benefit sharing for access to biological resource for commercial utilisation (Percentage of annual gross ex-factory sale price of product excluding Government taxes)
(1)(2)(3)
1.Up to 5 croreNil
2.Above 5 crore to 50 crore0.2%
3.Above 50 crore to 250 crore0.4%
4.Above 250 crore0.6%

Biological resources having conservation or high economic value, including species notified under Section 38 of the Act are subject to 20% more than the benefit sharing due.

If access is made to a biological resource that has conservation value, or high economic value such as red sanders, sandalwood, agarwood, or any other item identified by the Authority, including threatened species listed under Section 38 of the Act, the ABS component shall not be less than five percent of the proceeds of the auction or sale amount, or purchase price, as the case may be. This amount will be decided by the Authority on a case-by-case basis and must be paid as an upfront payment.

12. What are the forms applicable for IPR?

e-FormsPurpose of the application
6Application for seeking prior approval to use the results of research for obtaining IPR by the transferee (Section 3(2) entity).
7Application for seeking prior approval of the NBA before grant of IPR by persons covered under Section 3 (2) of the Act.
8Application for registration with the NBA before grant of IPR by persons covered under Section 7 of the Act.
9Application for seeking prior approval of the NBA for commercialisation of IPR by persons covered under Section 7 of the Act.
Applications are available in ABS e-filing portal

13. Are there specific Rules governing the implementation of the Biological Diversity Act? Have any amendments been made to these Rules?

Yes. - The Biological Diversity Rules, 2004 were notified by the Ministry of Environment, Forest and Climate Change (MoEFCC) on April 15, 2004 which came into force on July 01, 2004.

Pursuant to the amendments to the BD Act in 2023, the MoEFCC notified the Biological Diversity Rules, 2024 on October 22, 2024, thereby superseding the BD Rules, 2004. The BD Rules, 2024 came into force on December 21, 2024 upon expiry of 60 days from the date of notification in accordance with rule 1(2) of the BD Rules, 2024.

Further the BD Rules, 2024 were amended vide Biological Diversity (Amendment) Rules, 2025 which were notified on May 06, 2025 and came into force on November 01, 2025.

14. What constitutes an approval under this Act? How will I be informed about the approval of my application by the NBA to access a biological resource?

Approval shall be granted in the form of an agreement executed between the applicants and the NBA. The agreement shall contain the benefit sharing component, terms and conditions subject to which the applicant shall access the biological resources for research/commercial utilization/bio-survey and bio-utilization/IPR.

15. What should a Section 3(2) entity do when it accesses a biological resource from a trader or the wholesale market in India for commercial utilization?

If a Section 3(2) entity accesses biological resources from any place or location within India, including from a trader or the wholesale market or institute or repository in India, it is mandatory to obtain prior approval from the NBA by applying in Form-2 for accessing the biological resources for commercial utilization under Section 3 of the BD Act read with Rule 13 of the BD Rules, 2024.

16. Does a company's obtaining approval under the PPVFR Act require approval of the NBA for the activities envisaged under the BD Act?

No. As per Section 59A of the Act, the provisions of the BD Act shall not apply to a person who has been granted approval or rights under the PPVFRA, to the extent that such approvals or rights do not require similar approval under the BD Act.

17. What is a foreign-controlled company?

A “Foreign controlled company” means any company incorporated or registered in India under any law for the time being in force, which is controlled by a foreigner within the meaning of clause (27) of Section 2 of the Companies Act, 2013.

Under Section 2(27) of the Companies Act, 2013 -“control” shall include the right to appoint majority of the directors or to control the management or policy decisions exercisable by a person or persons acting individually or in concert, directly or indirectly, including by virtue of their shareholding or management rights or shareholders agreements or voting agreements or in any other manner.


 

18. Under the BD Act, upfront payment is applicable for access to biological resources of high economic value. Do seeds of cultivated crop fall under this category? If yes, which crop or types of seeds would upfront payment be applicable under the Act?

In case of biological resource having conservation value or high economic value such as red sanders, sandalwood, agarwood or any other items as decided by the Authority from time to time, and including threatened species notified under section 38 of the Act, the benefit sharing shall not be less than 5% of the proceeds of the auction or sale amount or the purchase price, as the case may be, as determined by the Authority on case to case basis, as upfront payment. This includes from both cultivated and non-cultivated biological resources

19. Do companies need to apply for approval to transfer of biological resources which are company-owned materials, for genotyping outside India (results to be used in the Indian breeding programme)?

The Act does not recognise a category called 'company-owned material', while dealing with biological resources. Hence the recipient/user of the biological resource needs to obtain approval of NBA under Section 3 of the Act if the biological resources contain any strain of an Indian germplasm.

20. Whether the consent of the local community (ies) is required for granting approvals by the NBA or SBBs/UTBCs on the applications for accessing biological resources?

Yes. Upon receipt of an application for access to biological resources, the NBA forwards the application to the concerned SBB(s) for obtaining the consent or otherwise of the relevant BMC(s) through a consultative process in the area from where the biological resources are obtained/accessed. The BMC is responsible for facilitating the task of obtaining prior informed consent from the concerned local communities or individual benefit claimants, if any. A similar procedure is followed by the SBBs in the respect of applications submitted by the applicants other than those covered under Section 3(2) of the Act.

FAQ Disclaimer

Version of FAQ: 

Date of FAQ: